Rineterkib

Customer Review

Based on 1 Customer Validation

Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF.

For research use only. We do not sell to patients.

  • Purity: 98.79%
  • CAS No.: 1715025-32-3
  • Formula: C26H27BrF3N5O2
  • Molecular Weight:578.42
  • Storage:

    4°C, sealed storage, away from moisture and light

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs

All ERK Isoforms

More

All Raf Isoforms

More
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00